SPRO - スマ―トプロス （Spero Therapeutics Inc.） スマ―トプロスSPROのチャート
SPROの企業情報
| symbol | SPRO |
|---|---|
| 会社名 | SmartPros Ltd （スマ―トプロス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 工業（Industrials） |
| 概要 | 事業概要 スペル・セラピューティックス(Spero Therapeutics Inc.)は臨床段階のバイオ医薬品会社である。同社は、MDR細菌感染の新規治療法の特定・開発・商業化に従事する。同社は、SPR994、増強剤プラットフォーム（SPR741とSPR206）、およびSPR720を含む新規製品候補のポートフォリオを開発している。SPR994はカルバペネム級の抗生物質であるテビペネムの新規経口製剤である。SPR994はMDR細菌感染に対して有効であり、その初期の焦点はcUTIの治療にある。ポテンシエータープラットフォームは、グラム陰性細菌に対する不活性抗生物質を含む既存の抗生物質のスペクトルおよび効力を拡大する薬物を開発することを可能にする。SPR720は、HIVを含む免疫系が損なわれた患者、または嚢胞性線維症、喘息及び気管支拡張症などの呼吸器疾患を有する患者にしばしば起こる、まれな肺感染であるNTMの治療のために設計された新規経口療法製品候補である。 スマ―トプロスは米国の教育サ―ビス会社。会計、金融サ―ビス、法務、エンジニアリング、証券、保険など、特定の市場を対象に教育・研修ソリュ―ションを提供。コ―スは、テキスト、ビデオ対話型、ライブ、オンラインセミナ―で利用できる。主な顧客は、大手企業及び、専門分野の会社や団体など。本社はニューヨーク州。 Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. |
| 本社所在地 | 12 Skyline Drive Hawthorne NY 10532 USA |
| 代表者氏名 | Milind S. Deshpande Milind S. Deshpande |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 857-242-1600 |
| 設立年月日 | 29677 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 57人 |
| url | www.smartpros.com |
| nasdaq_url | https://www.nasdaq.com/symbol/spro |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -44.37100 |
| 終値（lastsale） | 10.44 |
| 時価総額（marketcap） | 189678398.76 |
| 時価総額 | 時価総額（百万ドル） 183.13780 |
| 売上高 | 売上高（百万ドル） 3.20600 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 116.50080 |
| 当期純利益 | 当期純利益（百万ドル） -47.44600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Spero Therapeutics Inc revenues increased from $389K to $1.6M. Net loss applicable to common stockholders increased 7% to $20.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 18% to $15.8M (expense). |
SPROのテクニカル分析
SPROのニュース
GSK in a strong position to deliver growth from 2026 onwards 2023/02/01 07:39:56 DirectorsTalk
GSK plc (LON:GSK) has delivered strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations. Highlights Step change in commercial execution drives strong sales growth across Specialty Medicines and Vaccines · Sales of £29.3 billion +19% AER, +13% CER. Sales +15% AER, +10% CER excluding COVID-19 solutions · Specialty Medicines £11.3 billion +37% AER, +29% CER; HIV +20% AER, +12% CER; Oncology +23% AER, +17% CER; Immuno-inflammation and other specialty +29% AER +20% CER; COVID-19 solutions (Xevudy) sales £2.3 billion · Vaccines £7.9 billion +17% AER, +11% CER; Shingrix £3 billion +72% AER, +60% CER · General Medicines £10.1 billion +5% AER, +1% CER Prioritised investment and cost discipline support strong growth in operating profit and EPS · Total continuing operating margin 21.9%. Total EPS 371.4p > 100% primarily reflecting the gain from discontinued operations arising on the demerger of the Consumer Healthcare business.
After This Week’s 11.11% Gain In Spero Therapeutics Inc. (NASDAQ: SPRO), We Just Learned Something New 2023/01/14 12:00:00 Marketing Sentinel
Spero Therapeutics Inc. (NASDAQ:SPRO)’s traded shares stood at 0.43 million during the last session, with the company’s beta value hitting 0.78. At the close of trading, the stock’s price was $2.00, to imply an increase of 4.17% or $0.08 in intraday trading. The SPRO share’s 52-week high remains $13.35, putting it -567.5% down since that … After This Week’s 11.11% Gain In Spero Therapeutics Inc. (NASDAQ: SPRO), We Just Learned Something New Read More »
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference 2022/11/22 13:05:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:
Spero Therapeutics Inc. (SPRO) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/17 13:40:00 US Post News
In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]
Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. 2022/11/15 13:30:00 Marketing Sentinel
In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference 2022/11/22 13:05:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:
Spero Therapeutics Inc. (SPRO) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/17 13:40:00 US Post News
In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]
Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. 2022/11/15 13:30:00 Marketing Sentinel
In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »
Spero Therapeutics, Inc. (SPRO) Q3 2022 Earnings Call Transcript 2022/11/15 03:14:07 Seeking Alpha
Spero Therapeutics, Inc. (NASDAQ:NASDAQ:SPRO) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Ted Jenkins - Vice President, Investor Relations &…
Spero Therapeutics Earnings, Revenue Miss in Q3 By Investing.com 2022/11/15 00:14:00 Investing.com
Spero Therapeutics Earnings, Revenue Miss in Q3
Spero Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference 2022/11/22 13:05:00 GlobeNewswire
CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will participate in a fireside chat and be available for one-on-one meetings at the 5 th Annual Evercore ISI HealthCONx Conference, which is taking place virtually, November 29, 2022 through December 1, 2022. Details for the fireside chat are as follows:
Spero Therapeutics Inc. (SPRO) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/17 13:40:00 US Post News
In Wednesday’s session, Spero Therapeutics Inc. (NASDAQ:SPRO) marked $1.86 per share, down from $1.88 in the previous session. While Spero Therapeutics Inc. has underperformed by -1.06%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, SPRO fell by -88.71%, with highs and lows ranging from $17.08 to […]
Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. 2022/11/15 13:30:00 Marketing Sentinel
In the last trading session, 1.16 million shares of the Spero Therapeutics Inc. (NASDAQ:SPRO) were traded, and its beta was 0.77. Most recently the company’s share price was $2.03, and it changed around $0.03 or 1.50% from the last close, which brings the market valuation of the company to $69.43M. SPRO currently trades at a … Let’s Talk About How Spero Therapeutics Inc. (NASDAQ: SPRO) Stock Is Doing. Read More »